📣 VC round data is live. Check it out!

CollPlant Valuation Multiples

Discover revenue and EBITDA valuation multiples for CollPlant and similar public comparables like SpectraCure, Inventionmed, Predict, ScandiDos and more.

CollPlant Overview

About CollPlant

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.


Founded

1981

HQ

United States

Employees

57

Financials (FY)

Revenue: $2M
EBITDA: ($11M)

EV

$4M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CollPlant Financials

CollPlant reported last fiscal year revenue of $2M and negative EBITDA of ($11M).

In the same fiscal year, CollPlant generated $2M in gross profit, ($11M) in EBITDA losses, and had net loss of ($11M).

Revenue (LTM)


CollPlant P&L

In the most recent fiscal year, CollPlant reported revenue of $2M and EBITDA of ($11M).

CollPlant is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of (446%), and net margin of (485%).

See analyst estimates for CollPlant
Last FY202320242025202620272028
Revenue$2M$11M$515K$2M
Gross Profit$2M$9M($1M)$2M
Gross Margin65%82%(216%)65%
EBITDA($11M)($6M)($16M)($11M)
EBITDA Margin(446%)(58%)(3148%)(446%)
EBIT Margin(484%)(69%)(3350%)(484%)
Net Profit($11M)($7M)($17M)($11M)
Net Margin(485%)(64%)(3225%)(485%)

Financial data powered by Morningstar, Inc.

CollPlant Stock Performance

CollPlant has current market cap of $6M, and enterprise value of $4M.

Market Cap Evolution


CollPlant's stock price is $0.41.

CollPlant share price increased by 2.0% in the last 30 days, and decreased by 69.8% in the last year.

CollPlant has an EPS (earnings per share) of $-0.80.

See more trading valuation data for CollPlant
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4M$6M2.0%2.0%-23.5%-69.8%$-0.80

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CollPlant Valuation Multiples

CollPlant trades at 1.8x EV/Revenue multiple, and (0.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for CollPlant

EV / Revenue (LTM)


CollPlant Financial Valuation Multiples

As of June 2, 2026, CollPlant has market cap of $6M and EV of $4M.

CollPlant has a P/E ratio of (0.5x).

Last FY202320242025202620272028
EV/Revenue1.8x0.4x8.3x1.8x
EV/EBITDA(0.4x)(0.7x)(0.3x)(0.4x)
EV/EBIT(0.4x)(0.6x)(0.2x)(0.4x)
EV/Gross Profit2.8x0.5x(3.9x)2.8x
P/E(0.5x)(0.8x)(0.4x)(0.5x)
EV/FCF(0.5x)(1.2x)(0.3x)(0.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CollPlant Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CollPlant Margins & Growth Rates

In the most recent fiscal year, CollPlant reported gross margin of 65%, EBITDA margin of (446%), and net margin of (485%).

See estimated margins and future growth rates for CollPlant

CollPlant Margins

Last FY20242025202720282029
Gross Margin65%(216%)65%
EBITDA Margin(446%)(3148%)(446%)
EBIT Margin(484%)(3350%)(484%)
Net Margin(485%)(3225%)(485%)
FCF Margin(398%)(2830%)(398%)

CollPlant Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(95%)360%
Gross Profit Growth(112%)(238%)
EBITDA Growth153%(35%)
EBIT Growth130%(33%)
Net Profit Growth137%(31%)
FCF Growth292%(35%)

Data powered by FactSet, Inc. and Morningstar, Inc.

CollPlant Operational KPIs

CollPlant's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for CollPlant
Last FY202320242025202620272028
Revenue per Employee$0.0M---
Opex per Employee$0.2M---
R&D Expenses to Revenue345%96%2042%345%
Opex to Revenue549%150%3134%549%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CollPlant Competitors

CollPlant competitors include SpectraCure, Inventionmed, Predict, ScandiDos, Spineway, Lucyd, Steakholder Foods, Qlife Holding, AMA Corp and Vicarious Surgical.

Most CollPlant public comparables operate across Medical Devices, 3D Printing, BioTech, DeepTech, Industry 4.0 and Longevity.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
SpectraCure--(1.9x)-
Inventionmed8.0x-21.0x-
Predict0.5x-4.4x-
ScandiDos0.8x-20.4x-
Spineway0.2x0.2x(3.7x)(3.4x)
Lucyd0.3x0.2x(0.1x)(0.1x)
Steakholder Foods--(0.5x)-
Qlife Holding199.0x-(3.5x)-

This data is available for Pro users. Sign up to see all CollPlant competitors and their valuation data.

Start Free Trial

CollPlant VC Funding History

Before going public, CollPlant raised $1M in total equity funding, across 1 round.


CollPlant Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-13Seed-$1M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CollPlant

When was CollPlant founded?CollPlant was founded in 1981.
Where is CollPlant headquartered?CollPlant is headquartered in United States.
How many employees does CollPlant have?As of today, CollPlant has over 57 employees.
Who is the CEO of CollPlant?CollPlant's CEO is Eran Rotem.
Is CollPlant publicly listed?Yes, CollPlant is a public company listed on Nasdaq.
What is the stock symbol of CollPlant?CollPlant trades under CLGN ticker.
When did CollPlant go public?CollPlant went public in 2021.
Who are competitors of CollPlant?CollPlant main competitors include SpectraCure, Inventionmed, Predict, ScandiDos, Spineway, Lucyd, Steakholder Foods, Qlife Holding, AMA Corp, Vicarious Surgical.
What is the current market cap of CollPlant?CollPlant's current market cap is $6M.
What is the current revenue of CollPlant?CollPlant's last fiscal year revenue is $2M.
What is the current EV/Revenue multiple of CollPlant?Current revenue multiple of CollPlant is 1.8x.
Is CollPlant profitable?No, CollPlant is not profitable.
How many companies CollPlant has acquired to date?CollPlant hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies CollPlant has invested to date?CollPlant hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CollPlant

Lists including CollPlant

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial